(Q47169238)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

2 references

8 December 2020

20 January 2021

0 references

Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

chronic renal insufficiency

8 April 2020

main subject

5 references

13 March 2019

2 August 2019

28 September 2019

2 October 2019

12 November 2019

1 reference

2 August 2019

xanthine oxidase inhibitor

0 references

1 reference

28 September 2019

1 reference

2 October 2019

1 reference

12 November 2019

1 reference

8 December 2020

1 reference

20 January 2021

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

Davide Bolignano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

Guido Gembillo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

author name string

Anna Pisano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

Graziella D'Arrigo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

Michele Buemi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

language of work or name

English

0 references

publication date

31 October 2017

8 references

13 March 2019

2 August 2019

28 September 2019

2 October 2019

12 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

8 December 2020

20 January 2021

International Journal of Molecular Sciences

9 references

13 March 2019

2 August 2019

28 September 2019

2 October 2019

12 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

29 May 2020

8 December 2020

20 January 2021

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

8 April 2020

copyright license

7 references

13 March 2019

2 August 2019

28 September 2019

2 October 2019

12 November 2019

8 December 2020

20 January 2021

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Management of Gout and Hyperuricemia in CKD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Time to target uric acid to retard CKD progression

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

The Dark Side of Blocking RAS in Diabetic Patients with Incipient or Manifested Nephropathy.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Allopurinol for the treatment of chronic kidney disease: a systematic review

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Safety and efficacy of allopurinol in chronic kidney disease

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Uric acid and chronic kidney disease: which is chasing which?

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Uric acid as a target of therapy in CKD.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Grading quality of evidence and strength of recommendations

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Measuring inconsistency in meta-analyses

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

A review investigating the effect of allopurinol on the progression of kidney disease in hyperuricemic patients with chronic kidney disease.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

A role for uric acid in the progression of renal disease

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5713253

The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients

14 August 2018

1 reference

12 December 2020

Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia

1 reference

12 December 2020

Effect of Febuxostat on the Progression of Renal Disease in 5/6 Nephrectomy Rats with and without Hyperuricemia

1 reference

12 December 2020

Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia

1 reference

12 December 2020

Identifiers

DOI

10.3390/IJMS18112283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29088122%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference